OSAKA, Japan, May 7, 2025 -

日本大阪，2025年5月7日 -

Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter 'Shionogi' or the “Company”) today announced that at the Board of Directors meeting held on May 7, 2025, it resolved to succeed to the pharmaceutical business of Japan Tobacco Inc. (Headquarters: Minato-ku, Tokyo; President: Masamichi Terabatake; hereinafter referred to as 'Japan Tobacco') (hereinafter referred to as 'JT Pharmaceutical Business' or the 'Business to be Split') through a company split (simplified absorption-type split) (hereinafter referred to as the 'Absorption-Type Split') and to acquire all issued shares of Akros Pharma Inc.

盐野义制药株式会社（总公司：日本大阪；首席执行官：手代木功博士；以下简称“盐野义”或“公司”）今日宣布，在2025年5月7日召开的董事会上，决议通过公司分立（简化吸收型分立）继承日本烟草公司（总部：东京都港区；总裁：寺畑正道；以下简称“日本烟草”）的医药业务（以下简称“JT医药业务”或“分立业务”）（以下简称“吸收型分立”），并收购Akros Pharma Inc.的全部已发行股份。

(a 100% sub-subsidiary of Japan Tobacco, headquartered in New Jersey, USA; hereinafter referred to as 'Akros') by Shionogi Inc., a group company of Shionogi in the USA (hereinafter referred to as the 'Share Acquisition'), and has entered into an agreement (hereinafter referred to as the 'Agreement') regarding the same..

（日本烟草公司100%控股的子公司，总部位于美国新泽西州；以下简称“Akros”）由盐野义制药集团旗下的美国盐野义有限公司（以下简称“股份收购”）进行收购，并就此事达成了协议（以下简称“协议”）。

In connection with the Agreement, the Company also resolved at the Board of Directors meeting held today to conduct a tender offer (hereinafter referred to as the 'Tender Offer') for the common shares of Torii Pharmaceutical Co., Ltd. (hereinafter referred to as 'Torii Pharmaceutical'), a consolidated subsidiary of Japan Tobacco, to make Torii Pharmaceutical a wholly-owned subsidiary of the Company (hereinafter referred to as the 'Full Ownership').

根据协议，公司还在今天举行的董事会上决定对日本烟草的合并子公司鸟居制药有限公司（以下简称“鸟居制药”）的普通股进行要约收购（以下简称“要约收购”），以使鸟居制药成为公司的全资子公司（以下简称“全资控股”）。

For details on the Tender Offer, please refer to the 'Notice of Commencement of Tender Offer for Shares of Torii Pharmaceutical Co., Ltd. (Securities Code: 4551)' released today..

有关要约收购的详情，请参阅今天发布的《关于开始收购鸟居制药株式会社（证券代码：4551）股票的要约通知》。

I.      Purpose of the Absorption-Type Split and Share Acquisition (hereinafter referred to as the 'Transaction')

I.     吸收型拆分与股份收购的目的（以下简称“交易”）

Shionogi's basic policy (SHIONOGI Group Heritage) is to always provide the best medicine (healthcare solutions) necessary to protect people's health. The Company engages in research and development, manufacturing, and sales activities of prescription drugs, over-the-counter drugs, and diagnostic agents.

盐野义制药的基本方针（SHIONOGI集团传统）是始终提供保护人类健康所必需的最佳药物（医疗保健解决方案）。公司从事处方药、非处方药及诊断剂的研发、生产和销售活动。

In 2020, the Company set forth the Vision (SHIONOGI Group Vision) that aims to achieve by 2030, 'Creating the Future of Healthcare with a New Platform,' and formulated the medium-term management plan Shionogi Transformation Strategy 2030 (STS2030) to realize this Vision. The Company is transforming into a Healthcare as a Service (HaaS) company that provides various healthcare services tailored to customer needs, not limited to the provision of prescription drugs, to comprehensively address the problems faced by patients and society worldwide..

2020年，公司提出了以“创建基于新平台的未来医疗”为目标的愿景（SHIONOGI集团愿景），并制定了实现该愿景的中期管理计划——盐野木转型战略2030（STS2030）。公司正在转型为一家医疗即服务（HaaS）企业，提供满足客户需求的多样化医疗服务，不仅限于处方药的供应，旨在全面解决全球患者和社会面临的各种问题。

From fiscal 2020 to fiscal 2022, the Company aimed to contribute to the early end of the COVID-19 pandemic by providing not only therapeutic drugs but also total care solutions for COVID-19, including detection (epidemic prediction), prevention, diagnosis, and mitigation of severe cases. As a result, the Company obtained domestic approval for the COVID-19 therapeutic drug Xocova at an unprecedented speed, advancing its drug discovery capabilities.

从2020财年至2022财年，公司旨在通过提供包括检测（疫情预测）、预防、诊断和重症缓解在内的新冠综合护理解决方案，而不仅仅是治疗药物，为新冠疫情的早日结束做出贡献。在此过程中，公司以空前的速度获得了新冠治疗药物Xocova的国内批准，推动了其药物研发能力的进步。

Additionally, the Company expanded its product and service offerings beyond prescription drugs, including its first vaccine and wastewater epidemiology survey service. Based on the achievements and lessons learned from these efforts, the path to realizing the SHIONOGI Group Vision became clearer, leading to the revision of STS2030 in 2023 and the start of STS2030 Revision..

此外，公司还扩展了其产品和服务范围，超越了处方药领域，包括推出了首款疫苗和废水流行病学调查服务。基于这些努力所取得的成就和经验教训，实现SHIONOGI集团愿景的道路变得更加清晰，从而在2023年对STS2030进行了修订，并启动了STS2030修订版。

In STS2030 Revision, the three years from fiscal 2023 to fiscal 2025 are positioned as STS Phase 2, with the basic policy of global top-line growth centered on the infectious disease area and fostering growth drivers through aggressive investment, accelerating growth through transformation. In research and development, the Company focuses on high-impact infectious diseases and high-impact QOL diseases as priority areas.

在STS2030修订版中，从2023财年至2025财年的三年被定位为STS第二阶段，其基本政策是以传染病领域为核心的全球营收增长，并通过积极投资培育增长动力，借助转型加速增长。在研发方面，公司聚焦高影响力的传染病和高影响力的QOL疾病作为优先领域。

In infectious diseases, the Company has developed many innovative new drugs, such as the anti-HIV drugs (dolutegravir and cabotegravir), the  for multidrug-resistant Gram-negative bacterial infections (cefiderocol), and the anti-influenza virus drug Xofluza, based on its strong foundation in small molecule drug discovery (creating drugs with molecular weights ranging from tens to hundreds).

在传染病领域，该公司凭借其在小分子药物发现方面的坚实基础（创造分子量从几十到几百不等的药物），开发了许多创新的新药，例如抗艾滋病药物（多鲁特格韦和卡博特韦）、用于治疗多重耐药革兰氏阴性菌感染的药物（头孢地罗）以及抗流感病毒药物Xofluza。

The Company aims to solve the problems faced by patients and society worldwide by further strengthening and expanding its strong foundation in small molecule drug discovery..

公司旨在通过进一步加强和扩大小分子药物发现的坚实基础，解决全球患者和社会面临的问题。

On the other hand, JT Pharmaceutical Business has been engaged in research and development of prescription drugs since entering the business in 1987, aiming to create first-in-class small molecule drugs through stable research and development investment. Currently, under the business purpose of 'valuing science, technology, and human resources and contributing to patients' health,' Japan Tobacco conducts research and development, while Torii Pharmaceutical handles manufacturing, sales, and promotion activities, building an integrated value chain and maximizing synergies within the group.

另一方面，JT制药业务自1987年进入该领域以来，一直致力于处方药的研发，通过持续稳定的投资推动研发，目标是创造首创新的小分子药物。目前，在“重视科学、技术和人力资源，为患者健康做出贡献”的经营理念下，日本烟草负责研发，而鸟居制药则负责生产、销售和推广活动，构建了一体化的价值链，并在集团内部实现协同效应的最大化。

JT Pharmaceutical Business focuses on three priority research and development areas: cardiovascular, renal, and muscle, 'immunology and inflammation, and central nervous system, with strengths in rapid clinical development through specialization on research and development in the small molecule drug discovery and collaboration between domestic and international research and development bases.

JT制药业务专注于三大优先研发领域：心血管、肾脏和肌肉、免疫学与炎症以及中枢神经系统，通过专攻小分子药物发现的研发，并且在国内外研发基地之间进行合作，在快速临床开发方面具有优势。

To deliver new drugs created in-house to patients as early as possible,  JT Pharmaceutical Business actively engages in out-licensing and partnerships with global mega-pharma companies, in addition to promoting in-house development..

为了尽快将内部研发的新药交付给患者，JT制药业务除了推进内部开发外，还积极与全球大型制药公司进行授权和合作。

Shionogi has been considering collaboration with JT Pharmaceutical Business and Torii Pharmaceutical since early 2024 to realize the Vision of 'Creating the Future of Healthcare with a New Platform' in STS2030 Revision. As a result of these considerations, the Company concluded that by adding the capabilities of JT Pharmaceutical Business, which has strengths in small molecule drug discovery and development , it would be possible to accelerate the  advancement of promising pipeline projects and  increase the responsiveness and efficiency of business operations through collaboration with the Company's pharmaceutical manufacturing functions.

自2024年初以来，盐野义制药一直在考虑与日本烟草制药业务（JT Pharmaceutical Business）和鸟居制药（Torii Pharmaceutical）合作，以实现STS2030修订版中“通过新平台创造医疗保健未来”的愿景。经过这些考量，公司得出结论，通过结合日本烟草制药业务在小分子药物发现和开发方面的优势，将能够加速有前景的管线项目的进展，并通过与其制药生产职能的合作提高业务运营的响应速度和效率。

In early August 2024, the Company proposed to Japan Tobacco the acquisition of JT Pharmaceutical Business and the full ownership of Torii Pharmaceutical, and after subsequent discussions, reached the Agreement. The Company believes that the Transaction will create a leading company that delivers innovative pharmaceuticals from Japan to the world, contributing to the health of patients and people worldwide, and contributing to the realization of a sustainable and healthy society.

2024年8月上旬，本公司向日本烟草公司提出收购JT制药业务及鸟居制药的全部股权的提议，经过后续讨论，达成了协议。本公司认为，本次交易将创造一家领先的公司，将日本的创新药物带给全世界，为全球患者和人民的健康做出贡献，并有助于实现可持续发展的健康社会。

The Company also believes that the Transaction will provide opportunities for the employees of JT Pharmaceutical Business (including group companies) to continue to thrive with peace of mind..

公司还相信，此次交易将为JT制药业务（包括集团公司）的员工提供安心发展的机会。

II.     Overview of the Absorption-Type Split

第二节 吸收型分体式概述

i.    Summary of the Absorption-Type Split

i. 吸收型分裂总结

(1)   Date

(1) 日期

(1)

(1)

Date of Board Resolution for Agreement

协议的董事会决议日期

May 7, 2025

2025年5月7日

(2)

(2)

Date of Agreement

协议日期

May 7, 2025

2025年5月7日

(3)

(3)

Date of Board Resolution for Absorption-Type Split Agreement

吸收型分割协议的董事会决议日期

September, 2025 (planned)

2025年9月（计划中）

(4)

(4)

Date of Absorption-Type Split Agreement

吸收型拆分协议日期

September, 2025 (planned)

2025年9月（计划中）

(5)

(5)

Effective Date of Absorption-Type Split

吸收型分立生效日期

December, 2025 (planned)

2025年12月（计划中）

(Note 1): The Absorption-Type Split falls under the simplified absorption-type split stipulated in Article 796,

（注1）：吸收型拆分属于第796条规定的简化吸收型拆分，

Paragraph 2 of the Companies Act for the Company, and Article 784, Paragraph 2 of the Companies Act for

《公司法》第2段对于公司而言，以及《公司法》第784条第2段对于

Japan Tobacco. Therefore, it will be carried out without the approval resolution of the shareholders'

日本烟草公司。因此，它将在没有股东批准决议的情况下进行。

meeting.

会议。

(Note 2): The schedule may be changed as necessary, considering the need for responses to approvals,

（注2）：考虑到对审批的回应需求，日程安排可能会根据需要进行更改，

registrations, notifications, etc., from relevant authorities, circumstances, and other various factors.

来自相关当局、情况和其他各种因素的注册、通知等。

(2) Method of Absorption-Type Split

(2) 吸收型分裂方法

The Company will be the succeeding company, and Japan Tobacco will be the splitting company.

公司将成为承继公司，而日本烟草将成为分立公司。

(3) Allocation of Consideration

(3) 对价的分配

The Company will pay 5,397 million yen to Japan Tobacco as consideration for the Absorption-Type

公司将向日本烟草公司支付5397亿日元，作为吸收型交易的对价。

Split.

分裂。

(4) Handling of Stock Acquisition Rights and Bonds with Stock Acquisition Rights

（4）股票收购权和附股票收购权债券的处理

Not applicable.

不适用。

(5) Increase or Decrease in Capital Due to Absorption-Type Split

因吸收型拆分导致的资本增减

Not applicable.

不适用。

(6) Rights and Obligations to be Succeeded

（六）应继承的权利和义务

The Company will succeed to the assets, liabilities, and contractual rights and obligations related to the

公司将继承与之相关的资产、负债以及合同权利和义务。

Absorption-Type Split, except for those separately specified in the Absorption-Type Split Agreement.

吸收型拆分，吸收型拆分协议中另行规定的除外。

(7) Prospects for Debt Performance

债务履行前景

The Company believes that there are no issues with performance of the debts that will become due after the effective date of the Absorption-Type Split.

公司认为，吸收型拆分生效日期后将到期的债务履行不存在问题。

ii.    Allocation of Consideration and Basis for the Absorption-Type Split

ii. 对价的分配及吸收型分立的基础

(1) Basis and Reason for Allocation of Consideration

(1) 考量分配的依据与理由

The allocation of consideration was agreed upon after comprehensive discussions between both

双方经过全面讨论后达成了对价分配的协议。

companies, taking into account the performance status and future prospects of the business to be

公司，考虑到业务的表现状况和未来前景

split.

分裂。

(2) Matters Related to Calculation

(2) 与计算相关的事项

The Company has not obtained a valuation report from a valuation institution in connection with the

公司尚未从估值机构获得与之相关的估值报告。

Absorption-Type Split.

吸收式分离。

(3) Prospect of Delisting and Its Reason

（3）退市前景及其原因

Since the consideration involves the exchange of money, there is no prospect of delisting.

由于考量涉及金钱的交换，因此没有退市的可能。

(4) Measures to Ensure Fairness

(4) 确保公平的措施

Not applicable.

不适用。

However, the Company has appointed Nishimura & Asahi Law Office as the legal advisor for the

然而，公司已任命西村朝日律师事务所作为法律顾问。

Absorption-Type Split and has received legal advice on various procedures, decision-making methods,

吸收型分离，并已就各种程序、决策方法接受法律建议，

and processes related to the Absorption-Type Split. Nishimura & Asahi Law Office does not have any

与吸收型拆分相关的流程。西村朝日律师事务所没有任何相关信息

significant interests that should be disclosed in relation to the Absorption-Type Split and is not a

与吸收型拆分相关的应披露的重大利益，并非是

related party to the Company or Japan Tobacco.

与公司或日本烟草有关的关联方。

(5)Measures to Avoid Conflicts of Interest

(5)避免利益冲突的措施

Not applicable.

不适用。

(Unit: million yen, unless otherwise specified.)

（单位：百万日元，除非另有说明。）

i.    Overview of JT Pharmaceutical Business

i. JT制药业务概况

(1) Content of JT Pharmaceutical Business

(1) JT制药业务内容

Research and development of prescription drugs

处方药的研发

(2) Business Performance of JT Pharmaceutical Business

（2）JT制药业务的业绩表现

Fiscal year ended December 2024

截至2024年12月的财政年度

Net sales

净销售额

¥44,942 million

449.42亿元

(3) Items and Amounts of Assets and Liabilities of the JT Pharmaceutical Business to be Succeeded (as of December 31, 2024)

(3) JT制药业务将继承的资产和负债的项目及金额（截至2024年12月31日）

The assets (excluding shares of Torii Pharmaceutical and Akros) and

资产（不包括Torii Pharmaceutical和Akros的股份）和

liabilities, as well as other rights and obligations belonging to the JT pharmaceutical business, As

负债，以及属于JT制药业务的其他权利和义务，如

stipulated in the absorption-type split agreement will be succeeded by our company.

规定在吸收型分立协议中将由我公司继承。

Assets

资产

Liabilities

负债

field

字段

book value

账面价值

field

字段

book value

账面价值

Current Assets

流动资产

¥8,588 million

85亿8800万日元

Current Assets

当前资产

¥5,448 million

54亿4800万日元

Fixed Liabilities

固定负债

¥37,832 million

378.32亿元

Fixed Liabilities

固定负债

¥9,875 million

9875百万日元

Total

总计

¥46,420 million

464.2亿元

Total

总计

¥15,323 million

153.23亿元

Note: The above amounts are calculated based on the balance sheet as of December 31, 2024, and the actual amounts to be succeeded will be adjusted for any increases or decreases up to the effective date.

注意：上述金额是根据截至2024年12月31日的资产负债表计算的，实际承继的金额将根据生效日期前的任何增减进行调整。

ii.    Status After the Absorption-Type Split

ii.    吸收型分裂后的状态

(1)

(1)

Name of Company

公司名称

Shionogi & Co., Ltd.

盐野义制药株式会社

Japan Tobacco Inc.

日本烟草公司

(2)

(2)

Location

位置

1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan

日本大阪市中央区堂岛町3丁目1-8，邮编541-0045

1-1, Toranomon 4-chome, Minato-ku, Tokyo

东京都港区虎之门4丁目1-1

(3)

(3)

Representative

代表

Isao Teshirogi, Ph.D., Representative Director, President and CEO

铁城纪昭博士，代表董事，总裁兼首席执行官

Masamichi Terabatake, President, Chief Executive Officer and Representative Director

寺畑正道，总裁、首席执行官兼代表董事

(4)

(4)

Business Description

商业描述

Research, development, manufacturing and distribution of pharmaceuticals, diagnostic reagents and medical devices, etc.

药品、诊断试剂、医疗器械等的研究、开发、生产和分销等。

Manufacture, sale, import, etc., of manufactured tobacco

制造、销售、进口等烟草制品的生产

(5)

(5)

Paid-in Capital

实收资本

¥21,279 million

212.79亿元

¥100,000 million

￥100,000百万

(6)

(6)

Fiscal Year-End

财政年度末

March 31

3月31日

December 31

12月31日

(7)

(7)

Net Assets

净资产

It is not confirmed at this time

目前尚未确认。

It is not confirmed at this time

目前尚未确认。

(8)

(8)

Total Assets

总资产

It is not confirmed at this time

目前尚未确认。

It is not confirmed at this time

目前尚未确认。

iii.    Overview of Accounting Treatment

iii. 会计处理概述

For the accounting treatment related to the Absorption-Type Split, we plan to apply IFRS 3 'Business Combinations' and use the purchase method, with our Company as the acquiring entity. The amount of goodwill generated from this Absorption-Type Split is currently undecided, and we will inform you as soon as it is determined..

对于与吸收型分立相关的会计处理，我们计划采用《国际财务报告准则第3号——企业合并》（IFRS 3），并使用购买法，以本公司为收购主体。此次吸收型分立产生的商誉金额目前尚未确定，我们将在确定后尽快通知您。

iv.    Future Outlook

四. 未来展望

We are currently assessing the impact of this Absorption-Type Split on our consolidated performance, and will inform you as soon as it is determined.

我们目前正在评估本次吸收型拆分对我们合并业绩的影响，并将在确定后尽快通知您。

v.    Other Noteworthy Matters

v. 其他值得注意的事项

The Agreement is contingent upon the absence of any factors hindering the execution of the stock acquisition, such as the issuance of a cease and desist order, based on the results of the Japan Fair Trade Commission's review of the notification under Article 10, Paragraph 2 of the Act on Prohibition of Private Monopolization and Maintenance of Fair Trade..

本协议的前提是不存在任何阻碍股票收购执行的因素，例如基于日本公平贸易委员会根据《禁止私人垄断及确保公平交易法》第10条第2款对通知进行审查的结果而发布的停止令。

II.     Overview of this Stock Acquisition

第二节。本次股票收购概况

i.    Overview of Our U.S. Subsidiary (Shionogi Inc.) Acquiring the Shares

i. 我们美国子公司（盐野义公司）收购股份的概述

(1)

(1)

Name of Company

公司名称

Shionogi Inc.

盐野义制药株式会社

(2)

(2)

Location

位置

400 Campus Drive, Florham Park, NJ 07932, USA

美国新泽西州弗洛勒姆帕克，邮编07932，校园大道400号

(3)

(3)

Representative

代表

President and Chief Executive Officer

总裁兼首席执行官

Nathan McCutcheon

内森·麦卡锡

(4)

(4)

Business Description

商业描述

Development, manufacturing, and sales of pharmaceuticals

药品的开发、生产和销售

(5)

(5)

Paid-in Capital

实收资本

12 USD (as of March 31, 2024)

12美元（截至2024年3月31日）

(6)

(6)

Date of Founding

成立日期

August 2008

2008年8月

(7)

(7)

Major Shareholders and Shareholding Ratios

主要股东及持股比例

Shionogi (100%)

盐野义（100%）

ii.    Overview of the Subsidiary to be Acquired

ii.    拟收购子公司的概况

(1)

(1)

Name of Company

公司名称

Akros Pharma Inc.

阿克罗斯制药公司

(2)

(2)

Location

位置

302 Carnegie Center, Suite 300, Princeton, NJ 08540

302卡内基中心，300室，普林斯顿，新泽西州，邮编08540

(3)

(3)

Job Title and Name of Representative

职位名称和代表姓名

President＆CEO Teppei Higuchi

社长兼首席执行官樋口铁平

(4)

(4)

Business Description

商业描述

Clinical development, joint research, and exploration of new technology projects overseas

临床开发、共同研究以及海外新技术项目的探索

(5)

(5)

Paid-in Capital

实收资本

1,000 USD (as of December 31, 2024)

1,000美元（截至2024年12月31日）

(6)

(6)

Date of Founding

成立日期

January 1999

1999年1月

(7)

(7)

Net Assets

净资产

23,776 thousand USD (as of December 31, 2024)

23,776千美元（截至2024年12月31日）

(8)

(8)

Total Assets

总资产

32,986 thousand USD (as of December 31, 2024)

32,986千美元（截至2024年12月31日）

(9)

(9)

Major Shareholders and Shareholding Ratios

主要股东及持股比例

JT AMERICA INC. (100%) ※ JT AMERICA INC. is a wholly owned subsidiary of Japan Tobacco Inc.

JT AMERICA INC.（100%）※ JT AMERICA INC. 是日本烟草公司（Japan Tobacco Inc.）的全资子公司。

(10)

(10)

Relationship between Shionogi and said company

盐野义与该公司的关系

Capital Relationship

资本关系

None.

无。

Personal Relationship

人际关系

None.

无。

Transactional Relationship

事务性关系

None.

无。

Status as Related Party

关联方地位

None.

无。

iii.    Overview of the Counterparty in the Stock Acquisition

iii.    股票收购中对手方的概述

(1)

(1)

Name of Company

公司名称

JT AMERICA INC.

美洲JT公司

(2)

(2)

Location

位置

112 W. 34th Street, 18th Floors, New York, NY 10120

纽约州纽约市第34街西112号，18楼，邮编10120

(3)

(3)

Job Title and Name of Representative

职位名称和代表姓名

President & CEO Toshimitsu Eguchi

总裁兼首席执行官江口俊充

(4)

(4)

Business Description

商业描述

Holding company functions in the U.S. for non-tobacco and non-food businesses

美国非烟草和非食品业务的控股公司职能

(5)

(5)

Paid-in Capital

实收资本

51 thousand USD (as of December 31, 2024)

51,000美元（截至2024年12月31日）

(6)

(6)

Date of Founding

成立日期

May 1988

1988年5月

(7)

(7)

Net Assets

净资产

141,447 thousand USD (as of December 31, 2024)

141,447千美元（截至2024年12月31日）

(8)

(8)

Total Assets

总资产

142,125 thousand USD (as of December 31, 2024)

142,125千美元（截至2024年12月31日）

(9)

(9)

Major Shareholders and Ownership Ratios

主要股东及持股比例

Japan Tobacco Inc.(100％)

日本烟草公司（100%）

(10)

(10)

Relationship between Shionogi and said company

盐野义与该公司的关系

Capital Relationship

资本关系

None.

无。

Personal Relationship

人际关系

None.

无。

Business Relationship

业务关系

None.

无。

Related Party Relationship

关联方关系

None.

无。

iv.    Number of Shares to be Acquired, Acquisition Price, and the Status of Shareholding Before and After the Acquisition

iv. 收购股份数量、收购价格以及收购前后持股状态

* The acquisition price has been converted at an exchange rate of 1 USD = 151.55 JPY (based on the average rate over the past six months).

* 收购价格已按1美元=151.55日元的汇率进行了换算（基于过去六个月的平均汇率）。

v.    Date

v. 日期

vi.    Future Outlook

vi. 未来展望

We are currently assessing the impact of this stock acquisition on Shionogi’s consolidated financial results for the fiscal year ending March 2026. If it becomes necessary to revise the performance forecast, Shionogi will promptly disclose the information.

我们目前正在评估此次股票收购对盐野义制药截至2026年3月的财政年度合并财务结果的影响。如果有必要修改业绩预测，盐野义制药将迅速披露相关信息。

For Further Information, Contact:

如需更多信息，请联系：

SHIONOGI Website Inquiry Form:

盐野义制药网站咨询表：

https://www.shionogi.com/global/en/contact.html

https://www.shionogi.com/global/en/contact.html